Clozapine: a review of clinical practice guidelines and prescribing trends

BMC Psychiatry

Silvia Alessi-Severini¹  Stephanie Warnez¹ 

[1]Faculty of Pharmacy, University of Manitoba, Winnipeg, MB, Canada

关键词: Guidelines;    Utilization;    Antipsychotic(s);    Schizophrenia;    Prescribing;    Clozapine;   

Others  :  1123658
DOI  :  10.1186/1471-244X-14-102

 received in 2013-11-05, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

Clozapine effectiveness in the treatment of refractory schizophrenia has been sustained by published evidence in the last two decades, despite the introduction of safer options.

Discussion

Current clinical practice guidelines have strongly recommended the use of clozapine in treatment-resistant schizophrenia, but prescribing trends do not appear to have followed such recommendations. Clozapine is still underutilized especially in patients at risk of suicide. It seems that physicians are hesitant in prescribing clozapine due to concerns about serious adverse effects. Recent reports have highlighted the need to inform health professionals about the benefits of treating patients with clozapine and have voiced concerns about the underutilization of clozapine especially in patients at risk of suicide.

Summary

Guidelines and prescribing patterns reported in various countries worldwide are discussed. Suggestions on how to optimize clozapine utilization have been published but more efforts are needed to properly inform and support prescribers’ practices.

【 授权许可】

   
2014 Warnez and Alessi-Severini; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Crilly J: The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007, 18(1):39-60.
• [2]Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic, A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45(9):789-796.
• [3]Clozaril: Product Monograph. Health Canada http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=11421&lang=eng webcite Accessed on January 30, 2014
• [4]Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998, 59(Suppl 3):3-7.
• [5]Hartling L, Abou-Setta A, Dursum S, Mousavi SS, Pasichnyk D, Newton AS: Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications. Ann Int Med 2012, 157:498-511.
• [6]Leucht S, Cipriani A, Spinelli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet 2013, 382:951-962.
• [7]Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizoph Res 1999, 35:51-68.
• [8]Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with sec- ond-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
• [9]Alessi-Severini S, Biscontri R, Collins D, Kozyrskyj A, Sareen J, Enns M: Utilization and Costs of Antipsychotic Agents: a Canadian Population-Based Study: 1996–2006. Psychiatr Serv 2008, 59(5):547-553.
• [10]Pringsheim T, Lam D, Tano DS, Patten SB: The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009. Can J Psychiatry 2011, 56(10):630-634.
• [11]Aparasu RR, Bhatara V, Gupta S: US national trends in the use of antipsychotics during office visits, 1998–2002. Ann Clin Psychiatry 2005, 17:147-152.
• [12]Trifirò G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G: Antipsychotic prescribing pattern among Italian general practitioners: a population- based study during the years 1999–2002. Eur J Clin Pharmacol 2005, 61:47-53.
• [13]Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association; Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161(2):1-56.
• [14]Addington D, Bouchard RH, Goldberg J, Honer B, Malla A, Norman R, Tempier R, Berzins S: Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry 2005, 50(Suppl. 1):7S-57S.
• [15]Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas Medication Algorithm Project: antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007, 68:1751-1762.
• [16]National Institute of Health and Clinical Excellence: Core intervention in the treatment and management of schizophrenia in primary and secondary care (CG82) 2009. http://publications.nice.org.uk/schizophrenia-cg82 webcite Accessed January 30, 2014
• [17]Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36(1):71-93.
• [18]Clozapine Treatment of Hospitalized Patients: A Review of Clinical Practice Guidelines and Safety Report December 20, 2010 Accessed on August 10, 2012 http://www.cadth.ca/en/search?q=Clozapine webcite+treatment+in+hospitalized
• [19]Barnes TRE, Schizophrenia consensus group of the British Association for Psychopharmacology: Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011, 25(5):567-620.
• [20]Osser DN, Roudsari MJ, Manschreck T: The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry 2013, 21(1):18-40.
• [21]Moore TA, Covell NH, Essock SM, Miller AL: Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007, 30(3):401-416.
• [22]Taylor DM, Young C, Paton C: Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003, 64:30-34.
• [23]Wheeler AJ: Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008, 42:852-860.
• [24]Joober R, Boksa P: Clozapine: a distinct, poorly understood and underused molecule. J Psychiatry Neurosci 2010, 35(3):147-159.
• [25]Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D: Adherence to treatment to guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. BJP 2012, 201:481-485.
• [26]Alessi-Severini S, LeDorze JA, Nguyen D, Honcharik P, Eleff M: Clozapine prescribing in a Canadian outpatient population. Plos One 2013, 8(12):e83539.
• [27]Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effect of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994, 151:20-26.
• [28]Essock SM, Hargreaves WA, Covell NH, Goethe J: Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996, 32:683-697.
• [29]Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: Comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997, 337:809-815.
• [30]Chakos M, Lieberman JA, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001, 158:518-526.
• [31]Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
• [32]Essali A, Al-Haj HN, Li C, Rathbone J: Clozapine versus typical neuroleptic medications for schizophrenia. Cochrane Database Syst Rev 2010, 20(1):CD000059. pub2
• [33]Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006, 32(4):715-723.
• [34]Lieberman JA, Stroup S, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
• [35]Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK, CATIE Investigators: Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009, 107(1):1-12.
• [36]McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK, CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetipine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-610.
• [37]Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S: Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010, (11):CD006633.
• [38]Souza JS, Kayo M, Tassel I, Martins CB, Elkis H: Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from systematic review and meta-analyses. CNS Spectrums 2013, 18(2):82-89.
• [39]Duggan A, Wagner J, Knapp M, Kerwin R: Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia. BJP 2003, 182:505-508.
• [40]Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow up of mortality in patients with schizophrenia: a population-based cohort study (FIN 11 study). Lancet 2009, 374:620-627.
• [41]Kasckow J, Felmet K, Zisook S: Managing suicide risk in patients with schizophrenia. CNS Drugs 2011, 25(2):129-143.
• [42]Wasserman D, Rihmer Z, Rujescu D, Sarchiapone M, Sokolowski M, Titelman D, Zalsman G, Zemishlany Z, Carli V, European Psychiatric Association: The European Psychiatric Association (EPA) guidance on suicide treatment and prevention. Eur Psychiatry 2012, 27:129-141.
• [43]Conley RB, Kelly DL, Lambert TJ, Love RC: Comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatr Serv 2005, 56:320-323.
• [44]Goren JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS: Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 2013, 64(6):527-533.
• [45]Latimer E, Wynant W, Clark R, Malla A, Moodie E, Tamblyn R, Naidu A: Underprescribing of clozapine and unexplained variations in use across hospitals and regions in the Canadian province of Quebec. Clin Schizophr Relat Psychoses 2013, 7(1):33-41.
• [46]Malalagama G, Bastiampillai T, Dhillon R: Clozapine use in Australia. Australas Psychiatry 2011, 19(2):175.
• [47]Frogley C, Taylor D, Dickens G, Picchioni M: A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol 2012, 15:1351-1371.
• [48]“Clozaril” Prescribing information http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019758s069s071lbl.pdf Accessed January 30, 2014
• [49]Woerner MG, Robinson DG, Alvir JM, Sheitman BB, Lieberman JA, Kane JM: Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003, 160(8):1514-1526.
• [50]Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM: Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003, 28(5):995-1003.
• [51]Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB: Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007, 27(4):369-373.
• [52]Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA, CATIE Investigators: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007, 164(3):428-436.
• [53]Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K: A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010, 177(3):286-293.
• [54]Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A: Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull 2008, 34(6):1163-1171.
• [55]Chang YC, Lane HY, Yang KH, Huang CL: Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006, 26(6):554-559.
• [56]Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003, 160(11):2063-2065. Erratum in: Am J Psychiatry 2005, 162(9):1774
• [57]Gallego JA, Robinson DG, Sevy SM, Napolitano B, McCormack J, Lesser ML, Kane JM: Time to treatment-response in first –episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry 2011, 72:1691-1696.
• [58]Agid O, Arenovich T, Sajeev G, Kipursky RB, Kapur S, Foussias G, Remington G: An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011, 72(11):1439-1444.
• [59]Netherlands Clozapine Collaboration Group: Guideline for the use of clozapine [English version]. 2009. [Cited 14 July 2010] http://clozapinepluswerkgroep.nl/pdf/SKMBT_C45110040808460.pdf webcite
• [60]Schulte PF, Cohen D, Bogers JPAM, van Dijk D, Bakker B: A Dutch guideline for the use of clozapine. Aust N Z J Psychiatry 2010, 44:1055-1056.
• [61]Van-Kammen DP, Marder SR: Serotonin/dopamine antagonists. In Comprehensive Textbook of Psychiatry. 7th edition. Edited by Kaplan HI, Sadock BJ. Baltimore, Md: Lippincott Williams & Wilkins; 2000:2455-2473.
• [62]Hermes E, Resenheck : Choice of randomization to clozapine versus other second-generation antipsycotics in the CATIE schizophrenia trial. J Psychopharmacol 2012, 26:1194-1200.
• [63]Meltzer HY: Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012, 6(3):134-144.
• [64]Phanthunane P, Vos T, Whitefors H, Bertram M: Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. Cost Eff Resour Alloc 2011, 9:6. doi:10.1186/1478-7547-9-6 BioMed Central Full Text
• [65]Attard A, Taylor DM: Comparative Effectiveness of Atypical Antipsychotics in Schizophrenia. CNS Drugs 2012, 26(6):491-508.
• [66]Sinyor M, Remington G: Is psychiatry ignoring suicide? J Clin Psychopharmacol 2012, 32(3):307-308.
• [67]Hill M, Freudenreich O: Clozapine: key discussion points for prescribers. Clin Schizophr Relat Psychoses 2013, 6(4):177-185.
• [68]Damkier NJ, Taylor LH: Optimizing clozapine treatment. Acta Psychiatric Scand 2011, 123:411-422.
• [69]Beck K, Howes O: Optimising treatment of refractory schizophrenia. Psychopharmacology 2013, 227:373-374.
• [70]Williams T, Purvis TL: Development of an outpatient pharmacist-managed clozapine clinic. Am J Health-Syst Pharm 2012, 69:1192-1195.